Here are the 8-K filings from Aptorum Group Limited (APM) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow APM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APM filings page.
Niki BioSolutions, Inc., formerly known as Aptorum Group Limited, had previously been notified that its common stock traded below the $1.00 per share minimum bid price for 30 consecutive business days, triggering a deficiency under Nasdaq Listing Rule 5550(a)(2). The company was granted a 180‑day compliance period ending on September 1, 2026, during which it could regain compliance by maintaining a closing bid of at least $1.00 for ten consecutive business days.
Nasdaq subsequently informed the company on August 4, 2026 that, from July 21, 2026 to August 3, 2026, the closing bid price of its common stock was at or above $1.00 per share for ten consecutive business days. As a result, Niki BioSolutions has regained compliance with Nasdaq Listing Rule 5550(a)(2), and Nasdaq has indicated that this matter is now closed.
On July 20, 2026, Aptorum Group Limited completed its all-stock merger with DiamiR Biosciences Corp., after a domestication from Cayman to Delaware, and was renamed Niki BioSolutions, Inc.. Niki’s common stock now trades on the Nasdaq Capital Market under the symbol NIKI with CUSIP 653942 102.
As part of the transaction, each Aptorum Class A ordinary share converted 1-for-1 into Niki common stock, and each Class B ordinary share converted into one Niki common share plus one share of non-voting, non-convertible Series A Preferred Stock. Aptorum holders received 814,375 Niki common shares and 179,693 Series A Preferred shares, while DiamiR stockholders received 1,979,216 Niki common shares based on a defined Conversion Ratio. Immediately before closing, Aptorum implemented a 10-for-1 reverse share split, reducing outstanding Class A shares from 6,346,823 to 634,682 and Class B from 1,796,934 to 179,693. Niki adopted new Delaware charter documents, designated 1,810,000 preferred shares as Series A, and approved a 2026 Equity Incentive Plan reserving 4,500,000 common shares plus an annual evergreen increase.